European Psychiatry - Volume 41 - April 2017

173 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S106–S169 S169
3 The Department of Epilepsy, St. Petersburg Psychoneurological
Research Institute named after V.M. Bekhterev, Saint-Petersburg,
Russia
4 The Department of Clinical Pharmacology, The Krasnoyarsk State
medical University named after Prof. V.F. Voyno-Yasenetsky,
Krasnoyarsk, Russia
5 The Department of Management of Health Care, The Krasnoyarsk
State medical University named after Prof. V.F. Voyno-Yasenetsky,
Krasnoyarsk, Russia
6 The Department of Geriatric Psychiatry, St. Petersburg
Psychoneurological Research Institute named after V.M. Bekhterev,
Saint-Petersburg, Russia
∗ Corresponding author.
Introduction The gene CYP2D6 is of great interest also due to its
highly polymorphic nature, and involvement in a high number of
medication metabolisms. The presence of polymorphisms in the
CYP2D6 gene may modulate enzyme level and activity, thereby
affecting individual responses to pharmacological treatment.
Materials and methods Allele and genotype frequency distri-
butions of CYP2D6*10 variants and predicted phenotypes were
analyzed in blood samples of 123 patients (53 patients from
north-western region and 69 patients from Siberian region) using
polymerase chain reaction (PCR)-restriction fragment length poly-
morphism, PCR-single-strand conformation polymorphism.
Results The T/T, C/T, and C/C genotype frequencies of the
CYP2D6*10 allele were significantly different (P< 0.01) in regional
groups. The frequency of the wild homozygous variant C/C of
the CYP2D6*10 allele (extensive metabolizers) in the Siberian
region was the highest, while the north-western region of Russia
had the lowest frequency (P < 0.001), which are 82.6% and 64.2%,
respectively. The frequency of the heterozygous variant C/T of the
CYP2D6*10 allele (intermediate metabolizers) was significantly a
bit high in the north-western region, while the Siberian region of
Russia had the lowest frequency (P < 0.001), which are 35.8% and
17.4%, respectively. The homozygous variant T/T of theCYP2D6*10
allele (poor metabolizers) was not identified.
Conclusion The C100T polymorphism of the CYP2D6 gene may
be associated with several drug-induced reactions in patients with
depression, schizophrenia, epilepsy etc. The differences in the
prevalence of intermediate metabolizers in north-western and
Siberian regions of Russia may be due to genetic drift and accu-
mulation of alleles typical of European and Asian populations.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0190
Symptoms of anxiety during
pregnancy and metabolism: A pilot
metabolomics study
E. Toffol ∗, A.P. Elomaa , V. Glover , P. Kivimäki , M. Pasanen ,
L. Keski-Nisula , P. Huuskonen , S. Voutilainen ,
V. Velagapudi , S. Lehto
1 University of Helsinki, Institute of Behavioral Sciences, Helsinki,
Finland
2 University of Eastern Finland, Institute of Clinical
Medicine/Neurosurgery, Kuopio, Finland
3 Imperial College London, The Centre for Mental Health, London,
United Kingdom
4 University of Eastern Finland, Institute of Clinical
Medicine/Psychiatry, Kuopio, Finland
5 Faculty of Health Sciences, School of Pharmacy, University of
Eastern Finland, Kuopio, Finland
6 University of Eastern Finland, Institute of Clinical
Medicine/Obstetrics and Gynaecology, Kuopio, Finland
7 Department of Obstetrics and Gynaecology, Kuopio University
Hospital, Kuopio, Finland
8 University of Eastern Finland, Unit of Public Health and Clinical
Nutrition, Kuopio, Finland
9 University of Helsinki, Institute for Molecular Medicine Finland,
Helsinki, Finland
10 Department of Psychiatry, Kuopio University Hospital, Kuopio,
Finland
∗ Corresponding author.
Introduction Anxiety symptoms are frequent during pregnancy,
and they adversely affect pregnancy outcomes and offspring
development. The underlying biological mechanisms are not
known, but may in part be explained by alterations in cer-
tain maternal metabolic pathways. No metabolomic studies have
investigated possible metabolic alterations in anxious pregnant
women.
Objective This pilot study compared the metabolic profiles
of anxious and non-anxious pregnant women using a mass
spectrometry-based quantitative metabolomics system.
Methods Cases were 20 participants of the Kuopio birth cohort
study ) with first and third trimester symptoms
of anxiety (Edinburgh postnatal depression scale, anxiety sub-
scale – EPDS-3A ≥ 4), but no depression (EPDS≤ 12). Controls were
20 participants with low anxiety (EPDS–3A ≤ 3) and depression
(total EPDS≤ 9) in both the first and third trimester. Maternal
metabolic profiles were analyzed from serum samples drawnwhen
the mothers arrived at the delivery hospital.
Results Metabolic pathway analyses revealed significant enrich-
ment in the glycine, serine and threonine metabolism (P = 0.046),
as well as in the betaine (P = 0.048) metabolism pathways.
Homocysteine was the only metabolite to significantly differ-
entiate between cases and controls (VIP score 3.3), with lower
concentrations in cases (P = 0.003) even when excluding non-
users of folic acid supplementation ( n = 5; P = 0.002), C-sections
(n = 5; P = 0.013), or samples taken immediately postpartum (n = 2;
P = 0.004). No other metabolites significantly differed between the
groups.
Conclusions Physiological adaptation induced by pregnancy,
which may have homogenized the study populations, could
explain the only minor metabolic differences between the two
groups. Further research in larger samples, comparing metabolic
alterations in umbilical cord blood and maternal blood is
warranted.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.